Cardio-Oncology : Impact Factor & More
eISSN: 2057-3804pISSN: 2057-3804
Open AccessShare this on:
Key Metrics
CiteScore 
2.3
SNIP
0.88
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cardio-Oncology
Cardio-Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2090 | USD 2490 | GBP 1690 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2015 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC0 |
| OA statement | Visit website |
View less
Planning to publish in Cardio-Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cardio-Oncology
Cardio-oncology research prioritisation in the United Kingdom: national surveys of health care professionals, patients and carers.
- 20 May 2026
- Cardio-oncology (London, England)
From data to decision: a clinical pipeline for wearable AI in early cardiotoxicity detection.
- 18 May 2026
- Cardio-oncology (London, England)
SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model.
- 13 May 2026
- Cardio-oncology (London, England)
Role of ivabradine for anthracycline-induced cardiotoxicity: a meta-analysis.
- 9 May 2026
- Cardio-oncology (London, England)
Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis
- 9 May 2026
- Cardio-oncology
Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy.
- 8 May 2026
- Cardio-oncology (London, England)
Cardio-oncology research prioritisation in the United Kingdom: national surveys of health care professionals, patients and carers.
- 20 May 2026
- Cardio-oncology (London, England)
From data to decision: a clinical pipeline for wearable AI in early cardiotoxicity detection.
- 18 May 2026
- Cardio-oncology (London, England)
SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model.
- 13 May 2026
- Cardio-oncology (London, England)
Role of ivabradine for anthracycline-induced cardiotoxicity: a meta-analysis.
- 9 May 2026
- Cardio-oncology (London, England)
Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis
- 9 May 2026
- Cardio-oncology
Clinical utility of the HFA-ICOS risk tool in real-world HER2-positive breast cancer patients receiving therapy.
- 8 May 2026
- Cardio-oncology (London, England)
FAQs on Cardio-Oncology
How long has Cardio-Oncology been actively publishing? 
What is the publishing frequency of Cardio-Oncology?
How many articles did Cardio-Oncology publish last year?
What is the eISSN & pISSN for Cardio-Oncology?
What is Citescore for Cardio-Oncology?
What is SNIP score for Cardio-Oncology?
Who is the publisher of Cardio-Oncology?
